Piramal Pharma Completes Acquisition of Kenalog Injectable Product from Bristol-Myers Squibb
Piramal Pharma Limited has completed its acquisition of Kenalog, a branded commercial injectable product, from Bristol-Myers Squibb Company through its subsidiary Piramal Critical Care B.V. The transaction, finalized on 1st April, 2026, strengthens the company's Complex Hospital Generics portfolio and reinforces its market presence across the United States, Europe, and Asia Pacific regions. This strategic acquisition represents a significant milestone in expanding Piramal Pharma's specialized pharmaceutical offerings in the critical care segment.
